Artesunate/mefloquine (AS/MQ) — Competitive Intelligence Brief

Artesunate/mefloquine (AS/MQ) (Artesunate/mefloquine (AS/MQ)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Plasmodium falciparum (parasite); artesunate targets heme-dependent pathways; mefloquine targets parasite membrane and heme detoxification Infectious Disease Small molecule

Target snapshot

Artesunate/mefloquine (AS/MQ) (Artesunate/mefloquine (AS/MQ)) — Armed Forces Research Institute of Medical Sciences, Thailand. Artesunate and mefloquine are antimalarial agents that work synergistically to kill malaria parasites through distinct mechanisms: artesunate generates reactive oxygen species that damage parasite proteins and DNA, while mefloquine disrupts parasite membrane function and metabolism.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Artesunate/mefloquine (AS/MQ) TARGET	Artesunate/mefloquine (AS/MQ)	Armed Forces Research Institute of Medical Sciences, Thailand	marketed	Antimalarial combination	Plasmodium falciparum (parasite); artesunate targets heme-dependent pathways; mefloquine targets parasite membrane and heme detoxification
Atovaquone Proguanil and Artesunate Pyronaridine	Atovaquone Proguanil and Artesunate Pyronaridine	Armed Forces Research Institute of Medical Sciences, Thailand	marketed	Antimalarial combination	Plasmodium mitochondrial electron transport chain, dihydrofolate reductase, heme polymerase
Artesunate-amodiaquine fixed-dose combination	Artesunate-amodiaquine fixed-dose combination	Epicentre	marketed	Antimalarial combination	Plasmodium falciparum (multiple parasite targets)
Quinine plus sulfadoxine-pyrimethamine	Quinine plus sulfadoxine-pyrimethamine	Albert Schweitzer Hospital	marketed	Antimalarial combination	Plasmodium DNA/protein synthesis; dihydrofolate reductase; dihydropteroate synthase
artesunate-lapdap	artesunate-lapdap	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination	Plasmodium falciparum dihydrofolate reductase (lapdap component); artemisinin mechanism not fully elucidated but involves heme interaction
Artesunate + Amodiaquine	Artesunate + Amodiaquine	Professor Anders Björkman	marketed	Antimalarial combination	Plasmodium falciparum hemoglobin metabolism and DNA synthesis
Mefloquine and Dihydroartemisinin-piperaquine	Mefloquine and Dihydroartemisinin-piperaquine	University of Oxford	marketed	Antimalarial combination	Parasite heme polymerase (mefloquine); parasite proteins and lipids (dihydroartemisinin); hemozoin (piperaquine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class